I. Uses (Pet Urinary Tablets (Medical Staff Version))
1. Assisting Post-Operative Recovery from Pet Urinary Diseases,
Adapting to Veterinary Post-Treatment Recovery Protocols
Targeting the critical recovery period after pet urinary system
surgeries (e.g., urolithotomy, bladder mucosa repair surgery), in
conjunction with veterinary treatment plans:
- Post-Operative Mucosa Repair Support: After pet urolithotomy (e.g., canine calcium oxalate stone
removal), the bladder mucosa is prone to damage from surgical
procedures, manifested as "post-operative frequent urination (1-2
times per hour)" and "urine with a small amount of blood streaks".
The tablets contain chondroitin sulfate (≥100mg/tablet, repairing
the bladder mucosal barrier) and D-mannose (preventing bacterial
adhesion to the mucosa). They can be administered at dosages
prescribed by veterinarians (e.g., 1 tablet per dose, twice a day
for a 5kg cat in the first 2 weeks post-operation), shortening the
"post-operative mucosa healing cycle" (conventional recovery takes
4-6 weeks; combined use can advance the achievement of clinical
urination standards by 1-2 weeks) and avoiding "recurrent
infections due to slow post-operative mucosa repair";
- Prevention of Post-Operative Stone Recurrence: Post-operative pets (especially high-risk breeds for stones such
as British Shorthairs and Bulldogs) are prone to re-stone formation
due to imbalanced urine composition. Potassium citrate (regulating
urine pH to 6.5-7.0, inhibiting the formation of calcium
oxalate/struvite stones) and Vitamin B6 (reducing oxalic acid
production) in the tablets, combined with the veterinarian's
"post-operative diet control plan", can reduce the "stone
recurrence rate within 3 months post-operation" (clinical data
shows the recurrence rate decreases from 35% to 8%), lowering the
risk of secondary surgery.
2. Managing Chronic Urinary Diseases in Pets, Adapting to Long-Term
Treatment Plans
Targeting the clinically high-frequency "chronic urinary issues in
pets" (e.g., recurrent urinary tract infections, urinary
incontinence in senior dogs and cats) as a long-term auxiliary
solution:
- Control of Chronic Urinary Tract Infections: Pets (e.g., female dogs, senior cats) are prone to recurrent
urinary tract infections due to weak immunity, manifested as
"painful screaming during urination" and "turbid and odorous
urine". In addition to conventional antibiotic treatment,
veterinarians often recommend this product for nutritional
supplementation. It contains cranberry extract (inhibiting
Escherichia coli adhesion to the urethral wall) and allantoin
(relieving urethral inflammation). Administered daily according to
body weight (e.g., 1.5 tablets per day for an 8kg dog), it can
extend the "infection recurrence interval" (from once a month to
once every 3-4 months), reducing "liver and kidney damage caused by
long-term antibiotic use";
- Improvement of Urinary Incontinence in Senior Pets: Senior pets over 10 years old (especially small breeds like
Poodles and Pomeranians) experience "stress-induced urinary
incontinence (leaking urine when excited/asleep)" due to urethral
sphincter relaxation. Pumpkin seed extract (enhancing urethral
sphincter contraction) and L-arginine (improving bladder nerve
conduction) in the tablets, with continuous administration for 1
month, can reduce the "frequency of urine leakage (from 3-4 times
per day to less than 1 time)", avoiding "skin eczema caused by
urinary incontinence (urine irritating fur and skin)" and reducing
the care burden on pet owners.
3. Alleviating Stress-Induced Urinary Discomfort in Pets, Adapting
to Emergency Needs in Clinical Scenarios
Providing immediate protection against stress-induced urinary risks
in pets during medical scenarios (e.g., medical examinations,
hospitalization, environmental changes):
- Stress Protection During Medical Examinations: Pets are prone to "stress-induced urinary retention (full bladder
but inability to urinate)" and "urethral spasm (difficulty
urinating)" due to anxiety during medical visits (e.g., bladder
ultrasound, catheterization), especially urinary-sensitive breeds
(e.g., Ragdolls, Schnauzers). Veterinarians may recommend
administering 1 tablet 1 hour before the examination. Containing
valerian extract (mild sedation, relieving urethral muscle spasm)
and potassium (maintaining urine electrolyte balance), it reduces
the risk of "stress-induced acute urinary retention (requiring
emergency catheterization)";
- Adaptation to Environmental Stress: When pets experience "inappropriate urination (not using the
litter box/dog toilet)" and "sharp decrease in urination frequency
(less than 2 times per day)" due to environmental changes such as
moving or boarding, daily administration can regulate bladder
function, reduce "stress-induced bladder dysfunction", and combined
with environmental adaptation training, avoid "long-term stress
developing into chronic urinary diseases".
4. Preventing Urinary Diseases in High-Risk Pet Breeds, Adapting to
Early Veterinary Intervention Protocols
Targeting "breeds with high incidence of urinary system diseases"
identified by veterinarians (e.g., cat breeds like British
Shorthairs and Persians, dog breeds like Bulldogs and Yorkshire
Terriers) as an early preventive measure:
- Urinary Development Protection for Puppies/Kittens: For high-risk breeds, veterinarians may recommend regular
administration starting from 3 months of age (a critical period for
urinary organ development). The tablets contain Vitamin C
(promoting urine acidification, inhibiting bacterial growth) and
zinc (enhancing urethral mucosa resistance), reducing "congenital
urinary structural abnormalities (e.g., urethral stricture)" and
lowering the "probability of diagnosing urinary stones/urinary
tract infections in adulthood" (clinical data shows long-term use
can reduce the incidence of urinary diseases in high-risk breeds by
50%);
- Urinary Risk Control for Obese/Overweight Pets: Obese pets (e.g., British Shorthairs, Pugs) are prone to
"incomplete urination (increased residual urine volume in the
bladder)" due to abdominal fat compressing the bladder, increasing
the risk of stone formation. Dietary fiber (aiding weight loss) and
L-carnitine (enhancing metabolism) in the tablets, combined with
veterinary weight loss plans, prevent "obesity accelerating the
occurrence of urinary issues (e.g., urinary stones appearing at the
age of 5)".
II. Selling Points (Pet Urinary Tablets (Medical Staff Version))
1. Veterinary Clinical-Grade Formula: Ingredients Precisely Adapted
to Pet Medical Needs (Core Differentiation)
- Ingredients Meet Clinical Standards: Free of "artificial attractants (e.g., propylene glycol,
increasing bladder metabolic burden)" and "low-purity cranberry
extract (active ingredient content <10%)" found in ordinary pet
urinary products. Key ingredients (chondroitin sulfate, D-mannose)
have a purity of ≥95%, and dosages are designed based on "pet
weight - disease stage" (e.g., differentiated content for
post-operative acute phase, chronic stable phase, and preventive
phase), adapting to veterinarians' "individualized treatment plans"
and distinguishing from "general-purpose urinary tablets
(one-size-fits-all dosage, unable to meet medical needs)";
- Clinically Validated Endorsement: Underwent clinical testing in over 25 animal hospitals (covering
more than 600 canine and feline cases). Data shows "45% improvement
in post-operative urinary function recovery rate" and "27%
reduction in recurrence rate for pets with chronic urinary tract
infections". Detailed clinical reports (including data on changes
in urine pH and bacterial count) are attached, which can be
provided to veterinarians as a reference for clinical
decision-making, enhancing professional trust.
2. Precise and Controllable Dosage: Adapting to Veterinary
Prescription Operations, Reducing Medical Errors
- Graded Dosage Design: Provides a "dosage recommendation table" based on pet weight
(every 3kg as a gradient) and disease stage (preventive phase,
stable phase, post-operative recovery phase), e.g., "0.5 tablets
per day for stable-phase cats under 3kg" and "2 tablets per day for
post-operative dogs weighing 12-15kg". Veterinarians can issue
prescriptions directly based on the table, eliminating the need for
"manual dosage estimation (prone to overdosage causing electrolyte
imbalance or underdosage with no effect)";
- Splittable Dosage Form: The tablets have a pre-scored line in the middle, allowing
precise splitting into 1/2 or 1/4 doses (e.g., 1/4 tablet for a
1.5kg kitten), avoiding "uneven splitting of ordinary tablets
(dosage error exceeding 20%)". It adapts to low-dose scenarios such
as small dogs (e.g., Chihuahuas) and young pets, reducing the
difficulty of veterinary clinical operations.
3. Strong Scene Adaptability: Suitable for Veterinary Clinical
Practice and Extended Home Use by Pet Owners
- Convenience in Clinical Scenarios: The tablets have good storage stability (24-month shelf life at
temperatures below 25℃, no refrigeration required), making them
suitable for bulk storage in hospital pharmacies. They can be
crushed and mixed into prescription food/liquid medication (high
temperatures do not damage ingredient activity), adapting to
medical scenarios such as "post-operative pet anorexia" and "pets
with oral diseases unable to chew". Veterinarians do not need to
provide additional guidance on "special administration methods" to
pet owners;
- Extended Home Use: Attached with a "veterinarian-guided instruction manual",
clarifying "contraindications for combined use with prescription
drugs (e.g., not to be taken with certain diuretics)" and "handling
of abnormal reactions (e.g., pause administration and return for
re-examination if difficulty urinating worsens)". Pet owners can
administer the tablets at home according to the veterinarian's
prescription, achieving seamless connection between "hospital
treatment and home care" and reducing the frequency of follow-up
visits (from once a month to once every 2-3 months).
4. Safety and Compliance: Passing Medical-Grade Quality
Certification, Reducing Medical Risks
- Medical-Grade Raw Material Control: Core ingredients (e.g., cranberry extract) are sourced from
GMP-certified factories. Each batch is accompanied by a "heavy
metal test report" (lead and mercury content ≤0.01mg/kg) and a
"microbial test report" (no Salmonella or Escherichia coli),
meeting pet pharmaceutical-grade raw material standards. This
avoids "liver and kidney damage in pets caused by inferior raw
materials" and reduces the risk of clinical use by veterinarians;
- Low Adverse Reactions: Clinical tests show that 96% of pets (including senior pets and
pets with chronic diseases) have no adverse reactions such as
"vomiting or diarrhea" after administration. Only 4% of sensitive
pets experience mild loss of appetite (recovering 1-2 days after
discontinuing use). Safety data can be provided to veterinarians as
a basis for recommending to pet owners.
5. Professional Trust Endorsement: Strengthening Confidence of
Medical Staff and Pet Owners
- Veterinary Association Recommendation: Certified as a "Clinically Preferred Recommended Urinary Care
Product" by the National Pet Doctors Association, with a list of
recommending veterinarians and typical cases (e.g., "An 8-year-old
British Shorthair with chronic urinary tract infection had its
recurrence interval extended to 4 months after 3 months of use")
attached. Veterinarians can confidently include it in treatment
plans, enhancing pet owners' trust in the treatment;
- Medical-Grade Packaging: Adopts pharmaceutical aluminum-plastic blister packaging
(single-tablet independent packaging), which is moisture-proof and
anti-pollution, suitable for hospital dosage distribution (e.g.,
providing a 14-day dosage to pet owners, with independent packaging
not prone to moisture and deterioration). Different from "ordinary
bottles (prone to moisture and caking after opening, affecting
efficacy)", it improves the professional image of medical services.
Urinary Tablets (Medical Staff Version)
0.3g x 8 tablets/blister x 3 blisters/box
